LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

被引:0
|
作者
Yi Liu
Brian Debo
Mingfeng Li
Zhennan Shi
Wanqiang Sheng
Yang Shi
机构
[1] Harvard Medical School,Division of Newborn Medicine and Epigenetics Program, Boston Children’s Hospital
[2] University of Oxford,Ludwig Institute for Cancer Research
[3] Yale School of Medicine,Department of Neuroscience and Kavli Institute for Neuroscience
[4] Zhejiang University School of Medicine,Institute of Immunology, and Department of Respiratory Disease of The First Affiliated Hospital
[5] Hangzhou,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Exhausted CD8+ T cells are key targets of immune checkpoint blockade therapy and their ineffective reinvigoration limits the durable benefit in some cancer patients. Here, we demonstrate that histone demethylase LSD1 acts to enforce an epigenetic program in progenitor exhausted CD8+ T cells to antagonize the TCF1-mediated progenitor maintenance and to promote terminal differentiation. Consequently, genetic perturbation or small molecules targeting LSD1 increases the persistence of the progenitor exhausted CD8+ T cells, which provide a sustained source for the proliferative conversion to numerically larger terminally exhausted T cells with tumor-killing cytotoxicity, thereby leading to effective and durable responses to anti-PD1 therapy. Collectively, our findings provide important insights into epigenetic mechanisms that regulate T cell exhaustion and have important implications for durable immunotherapy.
引用
收藏
相关论文
共 50 条
  • [21] Predicting Tumor Response to PD-1 Blockade
    Ding, Li
    Chen, Feng
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (05): : 477 - 479
  • [22] Biomarkers of response to PD-1 pathway blockade
    Hanxiao Li
    P. Anton van der Merwe
    Shivan Sivakumar
    British Journal of Cancer, 2022, 126 : 1663 - 1675
  • [23] PD-1 Blockade - Signatures of Response and Resistance
    Chapuy, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 167 - 167
  • [24] Response and resistance PD-1 pathway blockade
    Topalian, Suzanne L.
    CANCER RESEARCH, 2015, 75
  • [25] HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
    Woods, David M.
    Sodre, Andressa L.
    Villagra, Alejandro
    Sarnaik, Amod
    Sotomayor, Eduardo M.
    Weber, Jeffrey
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) : 1375 - 1385
  • [26] T cell clonal proliferation early after PD-1 blockade
    Ono, Koya
    Onishi, Yasushi
    Kobayashi, Masahiro
    Hatta, Shunsuke
    Nasu, Kentaro
    Watanabe, Shotaro
    Ichikawa, Satoshi
    Okitsu, Yoko
    Fukuhara, Noriko
    Harigae, Hideo
    ANNALS OF HEMATOLOGY, 2019, 98 (01) : 219 - 220
  • [27] γδ T cell clonal proliferation early after PD-1 blockade
    Koya Ono
    Yasushi Onishi
    Masahiro Kobayashi
    Shunsuke Hatta
    Kentaro Nasu
    Shotaro Watanabe
    Satoshi Ichikawa
    Yoko Okitsu
    Noriko Fukuhara
    Hideo Harigae
    Annals of Hematology, 2019, 98 : 219 - 220
  • [28] Advanced Squamous Cell Carcinoma - Rapid Response to PD-1 Blockade
    Gellrich, F. F.
    Meier, F.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 16 - 16
  • [29] Blockade of PD-1 ligation reverses inhibition of T cell responses by hepatic stellate cells.
    Chen, CH
    Lu, LN
    Fung, JJ
    Qian, SG
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 327 - 327
  • [30] PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
    Xu-Monette, Zijun Y.
    Zhou, Jianfeng
    Young, Ken H.
    BLOOD, 2018, 131 (01) : 68 - 83